1477 — Ocumension Therapeutics Cashflow Statement
0.000.00%
- HK$8.50bn
- HK$7.68bn
- CNY417.31m
- 23
- 10
- 98
- 38
Annual cashflow statement for Ocumension Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -2,265 | -260 | -402 | -379 | -267 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 2,070 | 84.7 | 174 | 111 | 62 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -22.3 | -35.5 | -13.3 | 33.2 | -62.1 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -213 | -197 | -201 | -178 | -179 |
Capital Expenditures | -305 | -665 | -310 | -362 | -230 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 934 | -680 | 539 | 102 | 506 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 630 | -1,345 | 229 | -260 | 276 |
Financing Cash Flow Items | -82.4 | -10.7 | -1.79 | 119 | -2.25 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1,527 | 669 | -9.22 | 109 | -214 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1,842 | -909 | 44.8 | -327 | -114 |